[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/","commit":"e03f56897d","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for thirty approved products that had none","file":"src/data/spikes/cll.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Acalabrutinib\" }]"}]},{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/","commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"class"},{"field":"props"},{"field":"management"},{"field":"hepatic"},{"field":"source"}]},{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/cll.ts","type":"changed","fields":[{"field":"tldr","before":"\"A cleaner BTK blocker with fewer heart and bleeding problems than ibrutinib. In February 2026 it became half of the first all-oral, fixed-duration CLL regimen.\"","after":"\"Acalabrutinib is a cleaner BTK blocker with fewer heart and bleeding problems than ibrutinib. In February 2026 it became half of the first all-oral, fixed-duration CLL regimen.\""}]},{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/","commit":"713bfbdd72","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: AML, ALL, CLL deep dives (102 new entities: trials with structured outcomes, products with dosing/toxicity/regulatory events, target","file":"src/data/spikes/cll.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"mechanismSteps"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"regulatoryEvents"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"trials"}]}]